$AGIO Cashflow Statement | Understand Stock

$AGIO

$36.85 -$0.15 (0.41%) Close

$AGIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net (loss) income
Less: Net income from discontinued operations
Net loss from continuing operations
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Net accretion of discount on marketable securities
Gain on sale of contingent payments
Loss (gain) on disposal of property and equipment
Non-cash operating lease expense
Expense associated with license agreement
Realized gain on investments
Milestone payment from gain on sale of oncology business
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Other receivables
Prepaid expenses and other current and non-current assets
Accounts payable
Accrued expenses
Income taxes payable
Operating lease liabilities
Other liabilities
Net cash used in operating activities - continuing operations
Net cash used in operating activities - discontinued operations
Net cash used in operating activities
Investing activities
Purchases of marketable securities
Proceeds from maturities and sales of marketable securities
Proceeds from sale of contingent payments
Proceeds from milestone payment from gain on sale of oncology business
Payments associated with license agreement
Purchases of property and equipment
Proceeds from sale of equipment
Net cash provided by (used in) investing activities - continuing operations
Net cash provided by investing activities - discontinued operations
Net cash provided by investing activities
Financing activities
Payments on financing lease obligations
Purchase of treasury stock
Proceeds from public offering of common stock, net of reimbursements
Net proceeds from stock option exercises and employee stock purchase plan
Net cash provided by financing activities - discontinued operations
Net cash provided by financing activities

Net change in cash and cash equivalents
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period
Supplemental disclosure of non-cash investing and financing transactions:
Additions to property and equipment in accounts payable and accrued expenses
Operating lease liabilities arising from obtaining operating lease assets
Financing lease liabilities arising from obtaining financing lease assets
Net cash taxes paid

Comments